Roche: buying up for biotech boost

September 2005
PharmaWatch: Biotechnology;Sep2005, Vol. 4 Issue 9, p14
Market Research Report
The article report that Roche Holding AG has announced that it will acquire GlycArt Biotechnology AG for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology markets. The deal promises to strengthen Roche's drug development capabilities and help maintain the large increases in sales drawn from its therapeutic anti-cancer antibodies. Roche continues to expand and cement its position as one of the world's best-positioned pharmaceutical companies.


Related Articles

  • Roche: buying up for biotech boost.  // PharmaWatch: Monthly Review;Sep2005, Vol. 4 Issue 9, p46 

    Reports that Roche Pharmaceuticals has signed a deal to acquire Swiss biotech firm GlycArt Biotechnology. Information on the similarities in the business strategy of both the companies; Reference to Roche's previous acquisition of a stake in Genentech Inc.; Focus on Roche's access to GlycArt's...

  • Roche: buying up for biotech boost.  // PharmaWatch: Cancer;Sep2005, Vol. 4 Issue 9, p17 

    The article reports on the announcement by Roche Pharmaceutical Co. that it will acquire GlycArt Biotechnology AG for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen...

  • ROCHE/GLYCART TO DISCOVER NEW THERAPEUTIC ANTIBODIES.  // Worldwide Biotech;Nov2004, Vol. 16 Issue 11, p5 

    Reports on the agreement between Roche and GLYCART to discover next-generation therapeutic antibodies using GlycoMabTM technology. Terms of the agreement; Factors that influenced Roche to license GlycoMabTM; Profile of GLYCART and Roche; Information on GlycoMab.

  • A question of strategy. Pavlou, Fedra // Pharmaceutical Technology Europe;Apr2009, Vol. 21 Issue 4, p3 

    The author reflects on the development of various acquisitions evolving in the pharmaceutical industries. The author notes that the acquisitions among these industries including that of Pfizer Inc. and Merck and Co. Inc., will create the most diversified companies in the global healthcare...

  • life sciences In Brief.  // Chemical Market Reporter;1/17/2005, Vol. 267 Issue 3, p14 

    The article presents news on various developments in the pharmaceutical industry. The article reports that Antisoma PLC, a Great Britain-based cancer drug development company, will acquire US-based Aptamera Inc. in a share-based transaction, valued at roughly £11.5 million. As part of the...

  • Pharma, Biotech Allies Replenish Pipeline. McGee, Patrick // Drug Discovery & Development;Aug2006, Vol. 9 Issue 8, p10 

    The article focuses on the significance of the merger between biotechnology company Genentech Inc. and Roche AG, a pharmaceutical firm, to the field of drug development in the U.S. The history of Genentech and how it was consolidated with Roche is discussed. Moreover, because of the risk of...

  • Goodbye Genentech, But No Obit for Biotech Yet, Please. Boggs, Jennifer // BioWorld Today;3/16/2009, Vol. 20 Issue 49, p1 

    The article focuses on the possible impact of the merger between Roche Holdings AG and Genentech Inc. on the biotechnology industry. In the said deal, Roche agreed to acquire the remaining shares of Genentech priced at $95 per share. Some speculate that the merger could have a large impact on...

  • Bayer Buys Roche Consumer Division. Houlton, Sarah // Pharmaceutical Executive;Sep2004, Vol. 24 Issue 9, p24 

    Reports on the acquisition of Roche's consumer division by Bayer, a pharmaceutical company. Plan of Bayer to double its over-the-counter drug sales; Increase in consumer health; Reputation of the firms in the drug industry.

  • Roche now has partner for Ventana Medical. Smith, Nicholas // Inside Tucson Business;3/23/2009, Vol. 18 Issue 43, p1 

    The article reports on the acquisition of Genentech Inc. by pharmaceutical giant Roche Holding AG in Tucson, Arizona. It is noted that Roche paid $46.8 billion for the 44 percent of Genentech stock, which amounted the purchase price of $95 per share. Meanwhile, Roche has estimated that the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics